PCR Biosystems Ltd

pcrbio.com

PCR Biosystems offers a range of best-in-class kits and reagents for real-time PCR, endpoint PCR and cDNA synthesis. Our reagents combine enhanced polymerases with highly developed reaction buffers and novel hot start chemistry to maximise yield and sensitivity from the simplest to most challenging of reactions. We continuously invest in research and development to bring innovative, high-performing products to market. Our products excel in yield, specificity, sensitivity and speed, giving your reaction the best chance of working as you want it to, first time.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie | February 11, 2021

news image

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

news image

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More

MedTech

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

news image

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More

Medical

PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE

Palatin Technologies, Inc | December 29, 2021

news image

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...

Read More
news image

Cell and Gene Therapy

ABBVIE AND CARIBOU BIOSCIENCES ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF CAR-T CELL THERAPEUTICS

AbbVie | February 11, 2021

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a ...

Read More
news image

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More
news image

MedTech

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More
news image

Medical

PALATIN ANNOUNCES INITIATION OF PIVOTAL PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE

Palatin Technologies, Inc | December 29, 2021

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...

Read More